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ABSTRACT
Obesity epidemic has been spread all over the world in the past few decades and has caused 
a major public health concern due to its increasing global prevalence. Obese individuals are 
at higher risks of developing dyslipidemic characteristics resulting in increased triglyceride 
and LDL-cholesterol content and reduced HDL-cholesterol levels. This disorder has profound 
implications  as  afflicted  individuals  have  been  demonstrated  to  be  at  increased  risk  of 
development  of  hypertension,  atherosclerosis,  type  2  diabetes  and  cardiovascular  diseases. 
Today, this phenotype is designated as metabolic syndrome. According to the criteria set by the 
International Diabetes Federation (IDF), for a patient to be diagnosed with metabolic syndrome, 
the person must have central obesity plus any two of the following conditions: raised TG, 
reduced HDL-cholesterol, raised blood pressure, and increased fasting plasma glucose. Current 
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guidelines 
for the treatment of patients with the metabolic syndrome encourage therapies that lower LDL 
cholesterol and TG and raise HDL-cholesterol. Primary intervention often involves treatment 
with statins to improve the lipid profiles of these patients. However, recent studies suggest the 
potential of newly identified drugs including thiazolidinediones, GLP-1 agonists, and DPP-4 
inhibitors that seem to be promising in reducing the level of progression of metabolic syndrome 
related disorders. This review discusses the current pharmacological treatments of the metabolic 
syndrome with the above mentioned drugs.
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I. Metabolic Syndrome
Metabolic  syndrome,  also  known  as  the  insulin 
resistance syndrome, is a cluster of correlated metabolic 
abnormalities including glucose intolerance (elevated 
fasting glucose), insulin resistance, obesity, dyslipidemia 
(reduced HDL cholesterol, elevated plasma triglycerides 
(TG), and increased LDL cholesterol), and hypertension 
(1,2). 
According to the International Diabetes Federation 
(IDF), for a patient to be diagnosed with metabolic 
syndrome, the person must have central obesity 
(defined by waist circumference with ethnicity specific 
values) plus any two of the following conditions: 
raised TG, reduced HDL cholesterol, raised blood 
pressure, and increased fasting plasma glucose (3). 
Metabolic syndrome has emerged in recent years as 
a major public health concern due to its increasing 
global  prevalence.  This  disorder  has  profound 
implications  as  afflicted  individuals  have  been 
demonstrated to be at increased risk of development 
of hypertension, atherosclerosis, type 2 diabetes and 
cardiovascular disease (2).
Prevalence of metabolic syndrome varies among 
different populations depending on gender, age, 
and ethnicity (4). Results from a population study 
in  Prevention  of  Metabolic  Disorders  Research 
Center  in  Tehran,  Iran  indicate  that  among  4018 
Iranian subjects 40 years and older, the prevalence 
of metabolic syndrome was 51.4% (5) hence putting 
Iranian  populations  at  high  risk  of  complications 
associated with this syndrome (i.e. cardiovascular 
diseases).  
Clinical  repercussions  of  the  metabolic  syndrome 
include alterations in glucose and lipid homeostasis 
of  which  insensitivity  to  the  actions  of  insulin  is 
a key feature. This ‘resistance’  to insulin action is 
thought to promote a dyslipidemic state in which 
hepatic gluconeogenesis, glucose output, and VLDL 
secretion are enhanced. Furthermore, normal post-
prandial suppression of adipose tissue lipolysis is 
compromised in the insulin resistant state leading to 
a persistent elevation in circulating free fatty acid 
(FFA) levels. Enhanced FFA mobilization triggers a 
variety of metabolic deficiencies including further 
decreases  in  insulin  sensitivity  and  subsequent 
development  of  hyperinsulinemia ( 6).  Current 
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inhibitors. In this review, current pharmacological 
treatment of the metabolic syndrome and its lipid 
complications with the above mentioned drugs will 
be discussed.
II.  Statins:  Effective  cholesterol  lowering  agents 
with multiple pleiotropic effects
Statins  are  a  class  of  drugs  that  in  their  active 
hydrolysed form are specific inhibitors of HMG-CoA 
reductase, the enzyme responsible for catalyzing the 
conversion of HMG-CoA to mevalonate, an early 
rate  limiting  step  in  the  cholesterol  biosynthesis 
pathway.  Inhibition  of  HMG-CoA  reductase  with 
statins has been shown to reduce the plasma levels 
of cholesterol and apoB-containing lipoproteins in 
hypercholesterolemic models (8). This is achieved 
through  increased  hepatic  cholesterol  uptake  due 
to  upregulation  of  the  LDL  receptor  as  well  as 
mechanisms  of  action  on  apoB,  such  as  reduced 
translocation across the endoplasmic reticulum (ER) 
membrane, increased intracellular degradation, and 
diminished lipoprotein assembly (9).
Statins  have  been  shown  to  influence  the 
secretion of both LDL and VLDL in patients with 
hyperlipidemia (10). More recently, statins were also 
found to be effective in reducing plasma TG levels, 
inhibiting  intracellular  cholesterol  biosynthesis 
and upregulating LDL receptor expression (11). As 
a result of many years of study, statins have been 
characterized  as  highly  effective  hypolipidemic 
agents  to  reduce  lipid  abnormalities  in  metabolic 
syndrome patients (12). Some of the most common 
statins currently in clinical use are as follows.
  
II-1. Atorvastatin 
As a member of the statin family, atorvastatin has 
been clinically shown to lower LDL-C levels and 
recent studies also show that it can also ameliorate 
hepatic lipoprotein overproduction (13). 
In  a  clinical  study  examining  the  effect  of 
atorvastatin, subjects with type 2 diabetes mellitus 
and  dyslipidaemia  (LDL-C  >100  mg/dl  in  those 
without coronary artery disease, n=77; LDL-C >70 
mg/dl in those with coronary artery disease, n=4) 
were initiated with 10 mg of atorvastatin daily. The 
mean  body  mass  index  among  men  and  women 
subjects  was  25.0  +/-  4  and  26.7  +/-  3.6  kg/m2 
respectively. Pretreatment mean HbA(1c) was 7.9 
+/- 1.8 % and total cholesterol, TG and HDL-C and 
LDL-C were 214 +/- 27 mg/dl, 164 +/- 63 mg/dl, 
46 +/- 6 mg/dl and 135 +/- 24 mg/dl respectively. 
After three months of treatment the mean decrease 
was 62 +/- 31 mg/dl in total cholesterol (p < 0.001), 
31 +/- 57 mg/dl in TG (p < 0.001), 51 +/- 27 mg/dl 
in LDL-C (p < 0.001) and 4 +/- 8 mg/dl in HDL-C 
(p < 0.001). The LDL-C level was reduced by 37.6% 
in these patients, from 135 +/- 24 mg/dl to 84 = 27 
mg/dl (p < 0.001) with 10 mg of atorvastatin daily. 
It was possible to achieve target LDL-C of less than 
National  Cholesterol  Education  Program  Adult 
Treatment Panel III (NCEP-ATP III) guidelines for 
the treatment of patients with the metabolic syndrome 
encourage  therapies  that  lower  LDL  cholesterol 
and  TG  and  raise  HDL  cholesterol ( 1).  Primary 
intervention often involves treatment with statins to 
improve the lipid profiles of these patients.
The  NCEP-ATP  III  criteria  for  the  metabolic 
syndrome are based on the presence of 3 or more 
of  the  followings:  increased  waist  circumference, 
elevated  triglyceride  levels,  blood  pressure ( BP), 
fasting glucose level, and reduced HDL-C levels. 
The  American  Heart  Association ( AHA)  and 
National Heart, Lung and Blood Institute (NHLBI) 
groups  affirm  the  overall  utility  and  validity  of 
the NCEP-ATP III criteria and proposed that they 
should  continue  to  be  used  with  modifications. 
The  modifications  include:  1-adjustment  of  waist 
circumference to lower thresholds when individuals 
or  ethnic  groups  are  prone  to  insulin  resistance, 
2-allowing  TG  and  HDL-C  levels  and  BP  to  be 
counted as abnormal when a person is prescribed 
drug  treatment  for  these  conditions,  3-clarifying 
that elevated BP is defined as an elevation of either 
systolic or diastolic BP, and 4-reducing the threshold 
for elevated glucose level from 110 mg per dL or 
higher to 100 mg per dL or higher.
The  International  Diabetes  Federation ( IDF)  has 
proposed  clinical  criteria  similar  to  those  of  the 
NCEP-ATP III with identical thresholds for TG and 
HDL-C levels, BP, and plasma glucose. The IDF 
criteria are different in that the waist circumference 
thresholds are adjusted to different ethnic group and 
gender and require that increased waist circumference 
to  be  considered  as  an  element  of  the  metabolic 
syndrome because abdominal obesity reflects both 
concepts  of  obesity  and  insulin  resistance ( 7).  In 
the  U.S.  population,  updated  NCEP-ATP  III  and 
IDF criteria identify essentially the same people as 
having the metabolic syndrome (7).
Recommendations for management of the metabolic 
syndrome are for the most part the updated NCEP-
ATP III and IDF reports. First-line recommendations 
for reducing Cardiovascular Heart Disease (CHD) 
risks include smoking cessation, reducing LDL-C 
levels, BP, and glucose levels to recommended goals. 
If the TG level is higher than 500 mg per dL, then 
lowering the TG level to 500 mg per dL or less takes 
primacy over LDL-C lowering. After LDL-C, TG, 
and non HDL-C goals are achieved, a fourth target 
is raising HDL-C level. No specific goals for raising 
HDL-C levels are specified. Lifestyle interventions 
include  weight  loss  in  obese  subjects,  increased 
physical activity, and dietary modification. 
LDL-lowering standard drugs are also recommended. 
These include statins and ezetimibe. Other newly 
identified drugs that reduce the level of progression 
of  metabolic  syndrome  related  disorders  include 
thiazolidinediones,  GLP-1  agonists,  and  DPP-4 
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100 mg/dl in 75.5% (n=58) in subjects without CHD 
(n=77) and less than 70 mg/dl in 75% (n=3) of those 
patients with CHD (n=4). The present study showed 
that in patients with type 2 diabetes mellitus, 10 mg 
of atorvastatin daily was safe, well tolerated, and 
effective in reducing LDL-C to target levels (14).  
Our laboratory has examined the mechanism of action 
of atorvastatin in animal models of insulin resistance 
such as the fructose-fed hamster. In a series of ex vivo 
experiments in fructose-fed Syrian golden hamsters, 
atorvastatin treatment was shown to block hepatic 
apoB overproduction induced by the development of 
insulin resistance. In this study, there was molecular 
evidence  of  improved  hepatic  insulin  sensitivity 
with atorvastatin treatment based on assessment of 
the  phosphorylation  status  of  the  insulin  receptor 
and the expression of protein tyrosine phosphatase-
1B. The improvement in insulin signalling was not 
mediated by a change in hepatic TG accumulation 
as no significant difference was observed in liver 
TG levels. Taken together, these data suggested that 
atorvastatin not only can reduce the LDL-C levels, 
but it may potentially contribute to enhanced hepatic 
insulin sensitivity. 
II.2. Simvastatin
Clinical  studies  have  recently  suggested  that 
statin  treatment  may  beneficially  elevate  plasma 
concentrations of HDL cholesterol in patients with 
hyperlipidemia  and  increase  the  anti-atherogenic 
involvement of this cholesterol in the blood vessels 
(15). Elevated plasma LDL cholesterol levels and 
low levels of HDL cholesterol are known risk factors 
for development and progression of atherosclerosis 
and coronary heart disease (16). 
Epidemiological  evidence  has  demonstrated  that 
elevated plasma levels of apoA1, the major HDL 
apolipoprotein, is a strong negative risk factor for 
the  development  of  coronary  heart  disease  (17). 
Normal  regulation  of  plasma  HDL  concentration 
is  directed  in  part  by  the  rate  of  synthesis  and 
secretion  of  apoA1  from  hepatocytes.  In  a  study 
conducted in our laboratory, simvastatin treatment 
was shown to acutely increase synthesis and secretion 
of apoA1 in both hepatoma cell line (HepG2) and 
primary  hepatocyte  cultures  derived  from  Syrian 
golden hamsters (15). This statin treatment caused 
the  greatest  increase  in  apoA1  levels  at  10  µM 
as  compared  with  control  cells.  Higher  doses  of 
simvastatin did not have a further stimulatory effect 
on apoA1 levels (15). 
Additionally  in  order,  to  determine  whether  the 
stimulatory  effect  of  simvastatin  on  apoA1  is  a 
classical effect of statins in general or specific to 
this drug, the effect of simvastatin on intracellular 
synthesis of apoA1was compared to the effect of 
lovastatin  in  both  HepG2  and  primary  hamster 
hepatocytes. The differential effect of both statins on 
HepG2 cell production of apoA1 in a dose response 
experiment showed that both statins exhibit a dose 
dependent effect on apoA1 synthesis and the greatest 
effect was observed following a 10µM treatment. 
However, simvastatin exhibited a more potent ability 
to increase apoA1 synthesis (44.3 ± 12.1%, 10 µM) 
in  comparison  with  lovastatin  (26  ±  2%,  10µM). 
These data indicate the specificity of the observed 
statin effects (15).
Clinical  studies  have  also  shown  that  simvastatin 
can potentially raise plasma HDL concentrations by 
as much as 17%. This beneficial effect together with 
reduced plasma LDL-cholesterol concentration are 
accompanied by significant reductions in the risk 
of morbidity in patients with coronary heart disease 
(42%) relative to patients receiving standard care (18). 
II.3. Rosuvastatin
Rosuvastatin is a new member of the statin family 
with  higher  efficacy  in  reducing  LDL  cholesterol 
than  other  statins  at  comparable  doses  (19)  by 
having  a  higher  number  of  binding  interactions 
with  HMG-CoA  reductase,  compared  to  other 
statins (20, 21). This enhanced binding may cause 
stronger inhibition of the enzyme and hence result in 
a greater therapeutic efficacy. As well, rosuvastatin 
has a longer half-time than other statins and a higher 
degree of selectivity for hepatic cells (the main site 
of cholesterol synthesis) compared to non-hepatic 
cells (22). 
In a study conducted by Park et.al, an open-labeled, 
randomized  trial  was  performed  to  compare  the 
effects  of  10  mg  of  rosuvastatin  and  10  mg  of 
atorvastatin on lipid and glycemic control in Korean 
patients with nondiabetic metabolic syndrome (23).
In total, 351 patients who met the modified NCEP-
ATP III criteria for metabolic syndrome with low-
density  lipoprotein  cholesterol ( LDL-C)  levels 
≥  130  mg/dL  were  randomized  to  receive  either 
rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg 
(n = 178) for over 6 weeks.
After 6 weeks of treatment, greater reductions in total 
cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p 
< 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, 
p < 0.001), non-high-density lipoprotein cholesterol 
(- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), 
and  apolipoprotein-B  (-  38.7  ±  18.85  vs.  -  32.57 
± 17.56%, p = 0.002) levels were observed in the 
rosuvastatin group as compared to the atorvastatin 
group. Overall, the percentage of patients attaining 
the NCEP ATP III goal was higher with rosuvastatin 
as  compared  to  atorvastatin ( 87.64  vs.  69.88%, 
p < 0.001). Hence, Rosuvastatin 10 mg was more 
effective than atorvastatin 10 mg in achieving NCEP 
ATP III LDL-C goals in patients with nondiabetic 
metabolic syndrome, especially in those with lower 
NCEP ATP III target level goals (23). 
III. Cholesterol Absorption Inhibitors
Cholesterol  absorption  inhibitors  are  a  class  of 149
medication that decrease the absorption of cholesterol 
in the small intestine and hence decrease its delivery 
to the liver hence allowing more cholesterol to be 
cleared from the blood. The intestine has a unique 
capability  to  act  as  a  gatekeeper  for  entry  of 
cholesterol into the body, and inhibition of intestinal 
cholesterol  absorption  is  now  widely  regarded  as 
an  attractive  non-statin  therapeutic  strategy  for 
dyslipidemia  prevention.  Here  one  of  the  most 
widely used subclasses of this group of cholesterol 
lowering medications, ezetimibe will be descussed.
III. 1. Ezetimibe
Ezetimibe  is  a  member  of  a  novel  class  of  lipid 
lowering  agents  known  as  cholesterol  absorption 
inhibitors  (24).  Ezetimibe  inhibits  the  intestinal 
absorption  of  dietary  and  biliary  cholesterol  by 
binding to the Niemann- Pick C1 Like 1 (NPC1L1) 
transport protein (25). At the FDA approved dose of 
10 mg/day, ezetimibe has been shown to provide a 
20–25% reduction in LDL cholesterol levels when 
administered as either monotherapy or in combination 
with a statin (21). It is recommend that when standard 
doses of statins are insufficient to achieve the goal 
LDL cholesterol of less than 100 mg/dL, either the 
statin dose should be increased or ezetimibe may 
be prescribed alongside the statins (26). Despite the 
absence of data evaluating the impact of ezetimibe 
on the progression of atherosclerosis in metabolic 
syndrome and cardiovascular disease patients, the 
number of prescriptions dispensed for ezetimibe to 
be taken alone or in combination with simvastatin 
has increased substantially from 2003 to 2006 in the 
USA (19).  
In April 2008, the ENHANCE (Ezetimibe and 
Simvastatin  in  Hypercholesterolemia  Enhances 
Drug Famil: Name, Functions and Applications:
Statins  Atorvastatin  a. 
-Lowers LDL-C levels
-Ameliorates hepatic lipoprotein overproduction
-Enhances hepatic insulin sensitivity and signaling
 Simvastatin b. 
-Lowers LDL-C levels
-Increases plasma concentrations of HDL-C through elevating plasma concentration of apoA1 in patients with hyperlipidemia
 Rosuvastatin c. 
-Has the highest efficacy in reducing LDL-C, apoB, and non HDL-C than other statins at comparable doses
Cholesterol   
Absorption 
Inhibitors
a. Ezetimibe
-Inhibits the intestinal absorption of dietary and biliary cholesterol
-Reduces the LDL-C levels by 20–25% when administered as either monotherapy or in combination with a statin
-Reduces C-reactive protein levels 
Insulin 
sensitizing 
agents
 Rosiglitazone a. 
-Ameliorates whole body insulin resistance 
-Improves hepatic insulin signaling
-Reduces hepatic lipoprotein over production
b. Metformin
-Reduces excessive rates of hepatic glucose production 
-Improves insulin-stimulated glucose utilization by extra hepatic tissues 
-Lowers circulating levels of plasminogen activator inhibitor-1, hence lowering atherothrombotic events
-Reduces progression to diabetes among overweight and obese glucose-intolerant individuals
-Decreases weight gain in part by reducing dietary energy intake
-A useful adjunct in insulin-requiring patients with type 2 diabetes
GLP-1 
Receptor 
Agonists
a. Exenatide
-Stimulates replication and inhibits apoptosis of islet beta cells 
-Sustains reductions in HbA1c levels with progressive loss of body weight
-Improves glycemic control as a result of progressive reductions in body weight
-Improves blood pressure, lipid profiles and hepatic transaminase levels 
-Reduces the infiltration of fat into liver
DPP-4 
Inhibitors
 Sitagliptin a. 
-Used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for 
treatment of diabetes mellitus type 2
-Improves glycaemic control in adults with type 2 diabetes 
-Not licensed for use in combination with insulin therapy
-Significantly reduces HbA1c and fasting plasma glucose levels
-Ameliorates insulin secretion through improving the proinsulin to insulin ratio 
Table 1. Current and emerging pharmacological treatments for the metabolic syndrome
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Atherosclerosis  Regression)  group  conducted 
a study  on  the  clinical  utility  of  ezetimibe  in 
hypercholesterolemic  patients  at  risk  for 
atherosclerosis (24). In this study, 720 patients 
with  hypercholesterolemia  were  randomized 
and  treated  with  a  combination  of  10  mg/day  of 
ezetimibe plus 80 mg/day of simvastatin over two 
years of follow-up and the results showed reduced 
LDL cholesterol and C-reactive protein levels to a 
significantly greater degree with this combination 
than  80  mg/day  of  simvastatin  monotherapy 
(p  < 0.01). However, despite these differences in 
cholesterol-lowering, no significant difference 
in  the  change  in  carotid  intima  media  thickness, 
a  measure  of  subclinical  atherosclerosis  and  the 
primary  endpoint  of  the  study,  was  observed  in 
either treatment group. The ENHANCE trial later 
raised  important  questions  regarding  whether 
ezetimibe impacts biological processes relevant to 
the  pathogenesis  of  atherosclerosis  in  addition  to 
lipid-lowering. 
Statins  have  been  shown  to  improve  endothelial 
mediated vasodilatory responses through increased 
nitric  oxide  bioavailability,  and  has  potent  anti-
inflammatory,  antioxidant,  and  antithrombotic 
properties  (27). These  effects  likely  contribute  to 
the positive impact of statins on clinical outcomes 
that cannot be accounted for by reduction in LDL 
cholesterol  alone  (27).  The  impact  of  ezetimibe 
on  these  processes,  which  are  integral  to  the 
pathogenesis of atherosclerosis, remains unclear.
Landmesser et al.(28) randomized 20 patients with 
New  York  Heart  Association  (NYHA)  class  III 
chronic heart failure and a mean LDL cholesterol of 
106 mg/dL to 4 weeks of 10 mg/day of simvastatin 
or  10  mg/day  of  ezetimibe  monotherapy  and 
evaluated  the  impact  on  endothelial  function. 
They  observed  that  simvastatin  and  ezetimibe 
combination treatment yielded equivalent reductions 
in  LDL  cholesterol  levels  in  comparison  with 
simvastatin monotherapy. This finding enabled them 
to compare the pleiotropic effects of each therapy 
directly. Endothelial function was assessed by radial 
artery  ultrasound  flow-mediated  dilation  (FMD), 
a noninvasive measure that quantifies the percent 
change  in  radial  artery  diameter  in  response  to 
reactive hyperemia. Compared with baseline, mean 
± SEM FMD significantly increased after 4 weeks of 
simvastatin treatment (from 5.1% ± 0.7% to 10.5% 
±  0.6%;  p  <0.01),  whereas  no  significant  change 
was observed with ezetimibe (from 5.8% ± 0.6% 
to 5.6% ± 0.5%). Interestingly, the improvement in 
FMD after simvastatin was paralleled by an increase 
in  endothelium-bound  extracellular  superoxide 
dismutase (ecSOD) activity, a vascular antioxidant 
enzyme, whereas no significant change in ecSOD 
activity  was  observed  with  ezetimibe. These  data 
suggest that the improvement in endothelial function 
conferred by simvastatin may have been mediated, 
at least in part, by an antioxidant mechanism. The 
number of functionally active endothelial progenitor 
cells  (EPCs)  isolated  from  peripheral  blood 
mononuclear cells was also significantly increased 
by simvastatin (p < 0.05), but not by ezetimibe.
While  some  studies  suggest  no  improvement  in 
the  endothelial  mediated  vasodilatory  response 
with ezetimibe treatment, other studies suggest the 
opposite. Ezetimibe therapy has yielded a positive 
effect  on  endothelial  function  in  trials  including 
patients with metabolic syndrome. First, an open-
label  pilot  study  was  conducted  in  14  men  with 
metabolic  syndrome  who  were  on  40  mg/day  of 
atorvastatin (29). Endothelial function was assessed 
by  venous  plethysmography  after  intrabrachial 
artery  acetylcholine  infusion  at  baseline  and  8 
weeks after a therapeutic switch to 10 mg/day of 
atorvastatin and 10 mg/day of ezetimibe. Although 
the reduction in LDL cholesterol (21.0%) was not 
significantly different compared with baseline, total 
cholesterol  (16.5%),  VLDL  cholesterol  (32.2%), 
and  TG  (34.9%)  were  significantly  lower  after  8 
weeks of treatment. However, due to reductions in 
total cholesterol and lack of a parallel comparison 
with statin monotherapy, the independent impact of 
ezetimibe on endothelial function in this population 
was difficult to ascertain. 
Another prospective, randomized, crossover study 
evaluated the impact of 80 mg/day of simvastatin 
and the combination of 10 mg/day ezetimibe and 
10 mg/day of simvastatin on endothelial function 
in 19 metabolic syndrome patients without a history 
of  cardiovascular  disease  (30). After  6  weeks  of 
treatment,  brachial  artery  FMD  was  measured 
before and 4 hrs after ingestion of an oral fat load 
(50  g  fat/m2  and  3.75  g  glucose/m2).  Despite 
similar reductions in total cholesterol and LDL over 
6 weeks (mean ± SE 7.6% ± 1.2% to 7.7% ± 1.6%; 
p  =  0.8),  the  combination  of  ezetimibe  and  low-
dose simvastatin, attenuated the acute reduction in 
endothelial function elicited by the oral fat load. 
These conflicting results are not conclusive and more 
research is required to be conducted on the effects 
of ezetimibe on endothelial function in metabolic 
syndrome.
IV. Insulin Sensitizers and PPAR γ agonists
Currently,  insulin  sensitizing  drugs,  such  as                     
metformin  and  thiazolidinediones,  are  part  of  the 
treatment of practically any type 2 diabetic patient 
and can also be used in patients with the metabolic 
syndrome. At the beginning of the therapy, metformin 
is often used; later, insulin sensitizers (PPAR-gamma 
stimulators) such as of rosiglitazone are also prescribed.
The  relevance  of  PPARgamma  (peroxisome-
proliferator-activated  receptor  gamma)  as  an 
important  therapeutic  target  for  the  treatment  of 
diabetes  arises  from  its  hypoglycaemic  effects  in 
diabetic patients and also from the critical role in the 
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regulation of cardiovascular functions. 
IV.1. Insulin sensitizing agents: Rosiglitazone and 
Metformin
Clinical studies on type 2 diabetes patients indicate 
that the combination therapy of rosiglitazone and 
metformin  have  the  highest  therapeutic  effects. 
In  a  randomized  double-blind,  controlled  trials 
undertaken in clinics in Canadian centres, 207 patients 
with  impaired  glucose  tolerance  were  randomly 
assigned to receive combination of rosiglitazone 
(2  mg)  and  metformin  (500  mg)  twice  daily  or 
matching placebo for a median of 3.9 years. Incident 
diabetes occurred in significantly fewer individuals 
in the active treatment group (n=14 [14%]) than in 
the  placebo  group  (n=41  [39%];  p<0.0001).  The 
relative  risk  reduction  was  66%  and  the  absolute 
risk reduction was 26% yielding a number needed 
to treat of 70 (80%) patients in the treatment group. 
Insulin sensitivity decreased by the end of study in 
the  placebo  group  and  remained  unchanged  with 
rosiglitazone  and  metformin  treatment  (p=0.0006 
between groups) (31). 
Postprandial  elevation  of TG-rich  lipoproteins  (TRLs) 
is a well-recognized feature of diabetic dyslipidemia 
and includes the accumulation of intestinally derived 
apolipoprotein B48 (apoB48)-containing lipoproteins 
(8). There is increasing evidence that TRLs, including 
the apoB48 intestinally derived lipoproteins, may be 
particularly atherogenic (32). To date, studies in rats 
and human have focused on the delayed clearance of 
TRLs as the dominant underlying mechanism for their 
postprandial accumulation in diabetes. The impaired 
removal of intestinally derived lipoproteins has been 
attributed  to  decrease  in  the  activity  of  lipoprotein 
lipase  (33)  and  apolipoprotein  composition  of  the 
carrier particles (34). 
Rosiglitazone treatment of the fructose-fed hamster 
has been shown to ameliorate whole body insulin 
resistance,  improve  hepatic  insulin  signalling, 
and  reduces  hepatic  lipoprotein  over  production 
(35,36).  Treatment  of  fructose-fed  hamsters  with 
rosiglitazone  resulted  in  an  approximately  50% 
lower  apoB48  secretion  rate  than  fructose  alone           
(p < 0.05), but treatment of chow fed hamsters with 
rosiglitazone  resulted  in  no  significant  change  in 
apoB48 secretion rate. 
The  principal  action  of  metformin  (dimethyl- 
biguanide) is  to  reduce  excessive  rates  of  hepatic 
glucose production and improve insulin-stimulated 
glucose utilization by extrahepatic tissues. 
Metformin  targets  the  enzyme  adenosine  5’mono-
phosphate  activated  protein  kinase  (AMPK)  (37, 
38).  AMPK  regulates  cellular  glucose  and  lipid 
metabolism  through  phosphorylation  of  the  main 
proteins that affect energy production. Metformin 
lowers circulating levels of plasminogen activator 
inhibitor-1,  which  may  contribute  to  fewer 
atherothrombotic  events  (38).  In  the  Diabetes 
Prevention Program, metformin has been shown to 
reduce progression to diabetes among overweight 
and obese glucose-intolerant individuals (39). It may 
decrease  weight  gain  in  part  by  reducing  dietary 
energy intake, and is widely regarded as a useful       
adjunct  in  insulin-requiring  patients  with  type  2 
diabetes. 
V. Drugs acting on the Incretin System
A major and progressive defect in type 2 diabetes is 
the relative reduction in the ability of glucose to trigger 
insulin secretion from beta cells (38). Enhancing insulin 
secretion through a glucose dependent mechanism has 
been  considered  an  attractive  therapeutic  approach 
since it can restore the defective physiological pathway 
in type 2 diabetes patients and minimize the risk of 
hypoglycaemia. 
Gastrointestinal polypeptide hormones that are secreted   
in response to ingestion of a meal augment postprandial 
insulin secretion. This is known as the incretin effect 
and can account for up to 70% of postprandial insulin 
secretion (40). Quantitatively, the two most important 
incretin  hormones  are  glucagon-like  peptide-1 
(GLP-1)  and  glucose  dependent  insulinotropic 
peptide (GIP). These hormones are secreted by the L 
cells of the distal ileum and colon, and the K cells of 
duodenum and upper jejunum respectively. Circulating 
concentrations of incretins rise within a few minutes 
of eating, implying likely stimulation via activation 
of neuroendocrine pathways. Incretins act via specific 
G-protein coupled receptors on beta cells to enhance 
glucose-stimulated  insulin  secretion  (41). The  acute 
effect of GLP-1 on beta cells is stimulation of glucose-
dependent insulin release, followed by enhancement 
of insulin biosynthesis and stimulation of insulin gene 
transcription. 
The incretin effect is almost completely deficient in 
patients with type 2 diabetes mainly because of reduced 
postprandial GLP-1 secretion that is accompanied by 
reduced action of GIP (42). 
Administration of GLP-1 to individuals with type 2 
diabetes  increases  insulin  secretion  and  produces  a 
sustained dose dependent reduction in plasma glucose 
levels in concert with a reduction in body weight (43).
GLP-1 and GIP are subject to rapid degradation mainly 
by  the  ubiquitous  cell  surface  enzyme  dipeptidyl 
peptidase-4 (DPP-4), which cleaves two N-terminal 
amino acids thereby removing insulinotropic activity. 
Anti -diabetic DPP-4 inhibitors reduce serum activity of 
DPP-4 by 80% after a single dose through irreversible 
inhibition of the enzyme. 
Incretin mimetics fall into two categories: (i) derivatives 
of GLP-1 modified to resist proteolysis; and (ii) novel 
peptides that have metabolic action similar to GLP-1 
and are intrinsically resistant to proteolysis (44).
V.1. Glucagon-Like Peptide-1 Receptor Agonists
V.1.1 Exenatide
A DPP-4-resistant agonist for the GLP-1 receptor, 
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exendin-4, was first isolated from the venom of the 
Gila monster (Heloderma suspectum), a lizard native 
to the south-western US and Mexico, in a systematic 
search for new therapeutic peptides [41]. Synthetic 
exendin-4,  known  as  exenatide,  was  approved  in 
2005 by the FDA and has subsequently been licensed 
in many other countries (38). Exenatide is delivered by 
twice-daily subcutaneous injections using a prefilled pen 
device. The drug is licensed as adjunctive therapy for 
patients with type 2 diabetes with inadequate glycaemic 
control who are taking metformin, a sulfonylurea, a 
thiazolidinedione,  a  combination  of  metformin  and 
a  sulfonylurea,  or  a  combination  of  metformin  and 
a  thiazolidinedione.  As  a  GLP-1  receptor  agonist, 
exenatide stimulates replication and inhibits apoptosis 
of islet beta cells (45) as well as improving first-phase 
insulin secretion (46).
Sustained  reductions  in  HbA1c  levels  with 
progressive  loss  of  body  weight  have  been 
demonstrated  during  long  term  treatment  with 
exenatide. A  systematic  review  and  meta-analysis 
trial of at least 12 weeks duration concluded that 
the  GLP-1  receptor  agonist  lowered  glycated 
haemoglobin compared with placebo (weighted mean 
difference –0.97%) and induced weight loss (1.4 kg 
and  4.8  kg  for  placebo  and  insulin  respectively). 
Further studies have shown that improvements in 
glycemic  control  are  sustained  with  progressive 
reductions in body weight (47). Glycaemic control 
and reduced body weight may be accompanied by 
improvements in blood pressure, lipid profiles and 
hepatic transaminase levels suggesting a reduction 
in the infiltration of fat into liver (48).
V.2. Dipeptidyl Peptidase-4 Inhibitors
Pharmaceutical  inhibitors  of  DPP-4  are  agents 
taken  orally  that  acutely  increase  postprandial 
plasma  levels  of  endogenous  GLP-1  typically  by 
two  fold.  The  primary  target  of  these  drugs  are 
postprandial  hyperglycaemia,  although  fasting 
plasma glucose levels are also reduced. In clinical 
trials,  HbA1c  reductions  have  ranged  from  0.5–
1.1% in monotherapy when these agents have been 
administered at therapeutic doses once or twice daily. 
Greater reductions have been observed in patients 
with higher baseline HbA1c levels (49).
V.2.1. Sitagliptin
Prescription of sitagliptin (100 mg once daily) was 
approved  in  the  USA  in  2006  and  in  Europe  in 
April 2007 (49). As a DPP-4 inhibitor, sitagliptin 
is  indicated  as  an  adjunct  to  diet  and  exercise 
modifications to improve glycaemic control in adults 
with type 2 diabetes. Sitagliptin is not licensed for 
use in combination with insulin therapy. 
In  a  18  week  study  of  sitagliptin  monotherapy, 
521  adults  with  type  2  diabetes  treated  with  diet 
and exercise with a mean baseline HbA1c of 8.1% 
were randomized to treatment with placebo, or100 
mg or 200 mg of sitagliptin once daily. HbA1c was 
significantly reduced (–0.6%) with 100 mg daily of 
sitagliptin compared with placebo; 200 mg daily of 
sitagliptin was no more effective than 100 mg daily. 
Fasting proinsulin to insulin ratio were significantly 
improved  with  sitagliptin  treatment  while  the 
incidence  of  hypoglycaemia  and  gastrointestinal 
symptoms was not significantly different between 
sitagliptin  and  placebo  groups.  The  efficacy  and 
safety  of  sitagliptin, added  to  ongoing  metformin 
therapy, were assessed in 701 patients with type 2 
diabetes  who  had  inadequate  glycaemic  control 
(HbA1c ≥7% and ≤10%; mean 8.0%) with metformin 
alone. Mean duration of diabetes in these patients 
was ≈6–6.5 years and mean BMI ≈31 kg/m2. After a 
2-week, single-blind, placebo run in period, patients 
receiving ongoing metformin (>=1500 mg/day) were 
randomly assigned to receive placebo or 100 mg of 
sitagliptin once-daily in a 1 : 2 ratio for 24 weeks. At 
week 24, the addition of sitagliptin led to significant 
reductions in HbA1c (–0.65%), fasting plasma glucose 
and 2-hour post-meal glucose concentrations. Various 
measures  of  β-cell  function,  including  proinsulin 
to  insulin  ratio  were  significantly  improved  with 
sitagliptin compared with placebo. 
Concluding Remarks
The  metabolic  syndrome  is  a  constellation  of 
common metabolic disorders that is associated with 
type  2  diabetes  and  cardiovascular  disease.  Insulin 
resistance and dyslipidemia play central roles in the 
pathophysiology of this syndrome. Patients diagnosed 
with  metabolic  syndrome  often  exhibit  raised  TG 
and LDL cholesterol, reduced HDL cholesterol and 
raised blood pressure and fasting plasma glucose (3). 
Classical medications for the treatment of metabolic 
syndrome  include  LDL  cholesterol  lowering  agents 
such as the statins. However, recent studies show that 
increasing  insulin  sensitization  by  PPAR  γ  agonists 
(i.e. rosiglitazone) or augmenting postprandial insulin 
secretion using gastrointestinal polypeptide hormones 
can also ameliorate the complications caused by this 
syndrome.  Examples  of  these  recently  developed 
medications  have  been  discussed  in  this  review. 
Intense research is currently underway to develop new 
therapeutic strategies in the treatment and management 
of this very common and clinical important syndrome.
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